Companies › Abivax
1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Immunology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Obefazimod (ABX464) Cap binding complex modulator | NCBP2, NCBP1 | Phase 3 | Ulcerative Colitis; Moderately to Severely Active Crohn Disease; Healthy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07453784 | Obefazimod (ABX464) | Phase 1 | Healthy | Other | Sep 2026 |
| NCT06456593 | Obefazimod (ABX464) | Phase 2 | Moderately to Severely Active Crohn Disease | Immunology | Dec 2026 |
| NCT05177835 | Obefazimod (ABX464) | Phase 2 | Ulcerative Colitis | Immunology | Mar 2028 |
| NCT05535946 | Obefazimod (ABX464) | Phase 3 | Ulcerative Colitis | Immunology | May 2030 |
Cash and short-term investments of 538m EUR on 2025-12-31; operating cash outflow about 162m EUR a year; runway about 40 months at that burn, to Apr 2029; 2 of 3 coming phase 2-3 readouts fall inside that runway
Zhejiang Wenda Pharma Technology Shattuck Labs Veradermics Palvella Therapeutics Oruka Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.